MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13045-018-0686-1

Медицинская библиотека · Journal of hematology & oncology · 2019

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.

Chamoun Kamal, Kantarjian Hagop, Atallah Rami, Gonzalez Graciela Nogueras, Issa Ghayas C, Rios Mary Beth, Garcia-Manero Guillermo, Borthakur Gautam, Ravandi Farhad, Jain Nitin, Daver Naval, Konopleva Marina, DiNardo Courtney D, Kadia Tapan, Pemmaraju Naveen, Jabbour Elias, Cortes Jorge

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Patients with CML treated with TKI can have a life expectancy comparable to that of the general population. Due to the extended duration of TKI administration, treatment discontinuation has been increasingly sought.

METHODS

Medical records of 100 patients with CML who were in MR4.5 and discontinued their TKI outside clinical trials were reviewed.

RESULTS

After a median follow-up of 30 months (range, 5-112 months) after discontinuation, 35% and 17% lost MR4.5 and major molecular response (MMR), respectively. Only six patients lost MMR 12 months or more after discontinuation. Loss of MR4.5 was observed in 29% and 7% of patients with sustained MR4.5 duration of more than 2 and 6 years before discontinuation, respectively. By univariate analysis, there was a higher risk of loss of MR4.5 for patients who were treated for less than 87 months, received second or subsequent line TKI, never received interferon, or those with sustained MR4.5 for less than 6 years. By multivariate analysis, sustained MR4.5 for 6 years or more was the only significant predictor for durable response. Overall, 30% of patients who discontinued while in MR4.5 were retreated with 93% regaining MR4.5 at a median of 5 months.

CONCLUSION

These results demonstrate that under proper conditions, treatment discontinuation is feasible outside of clinical trial setting. MR4.5 duration of 6 years or more before discontinuation is associated with very low risk of loss of MR4.5.

Для цитирования: Chamoun Kamal, Kantarjian Hagop, Atallah Rami, Gonzalez Graciela Nogueras, Issa Ghayas C, Rios Mary Beth, Garcia-Manero Guillermo, Borthakur Gautam, Ravandi Farhad, Jain Nitin, Daver Naval, Konopleva Marina, DiNardo Courtney D, Kadia Tapan, Pemmaraju Naveen, Jabbour Elias, Cortes Jorge. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.. Journal of hematology & oncology. 2019. DOI: 10.1186/s13045-018-0686-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.